CDMO services for tomorrow's proteins

tailor-made
solutions

Contact us to discuss a project
We develop outstanding protein production processes for our customers. We do this by leveraging our proprietary expression technologies and extensive experience to engineer bespoke bacterial strains for each and every customer protein. The strains will give maximal titers of biologically active protein. The strains are then transferred to the customer for use under a license agreement, together with all required documentation and protocols.
A typical strain development project will consist of up to five work packages with go or no-go steps between. The first work package is a feasibility study, followed by work packages to optimize the genetics of the strain and to determine its optimal cultivation conditions. For most of our screening we are relying on microtiter scale, but all strains are tested at high cell-density fed-batch conditions. The end result is a research cell bank (RCB) together with full documentation of the development work.
WP
01
Feasibility and Strategy assessment
Feasibility and Strategy assessment
Screening of
  • - Plasmid copy numb.
  • - Signal peptides
  • - Fusion partners
  • - Expression strength
Screening of
  • - Chaperones
1st generation production strain
WP
02
Optimization of Genetics
Optimization of Genetics
Screening of
  • - Expression strength
  • - PCN optimization
2nd generation production strain
WP
03
Cultivation optimization & Scale-up
Cultivation optimization & Scale-up
Screening of
  • - Host strain
  • - Medium
  • - Harvest timepoint
  • - Induction OD
  • - Inducer conc.
Optimized cultivation protocol
Scale-up to HCDC
WP
04
Fed-batch optimization
Fed-batch optimization
Screening of
  • - Temperature
  • - Harvest time
  • - Feeding strategy
  • - Fed-batch media
Optimized fed-batch protocol
WP
05
Research cell bank
Research cell bank
Our clients

trusted by
the industry

CEO
Pharma company
“The Vectron technology outperforms any previous attempt to achieve a commercially viable yield/titre of our very difficult to express therapeutic protein.

The Vectron expression technology and the team have provided amazing results expressing our POI and ensured a path forward for our project.”
Read More
CEO
Enginzyme
“When all else failed, the VB-technology worked! When we wanted to get commercially viable yields of a difficult protein, we added VB to the engineering strategy, and thereby the yield was increased more than 10-fold. We are very happy to work with Vectron and have access to their innovative and powerful technology.”
Read More
Snr Director R&D
Pharma company
“I had a problem in the expression and the production of our protein in E. coli. In the feasibility study Vectron made every effort sincerely to find the solutions and Vectron’s technology gave higher expression titers than I expected. The results were promising and satisfactory.”
Read More
Head of Synthetic Biology
Undisclosed company
“Vectron conducted a large bioinformatics project for us which identified more than 100 unique proteins that match our application criteria, some of which were de novo designed and engineered by Vectron and many that posed very challenging manufacturing issues.

Vectron then used their innovative expression technology platform to express these proteins, resulting in 18 that were produced at high titers. Vectron has delivered excellent services at a highly competitive price, and we are excited to have initiated additional projects with this highly competent company.”
Read More
GET IN TOUCH
Do you want to know more about our innovative, proprietary technologies or how our services can help you?
CONTACT US